乐普医疗：控股子公司MWN109注射液Ⅱ期临床试验完成首例受试者给药

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary Minwei Biotech has initiated a Phase II clinical trial for the innovative drug MWN109 injection, aimed at treating overweight or obesity, with the first subject successfully dosed recently [1] Group 1: Drug Development - MWN109 injection is a GLP-1/GIP/GCG receptor triple agonist with global intellectual property rights [1] - The drug works by stimulating pancreatic β-cell insulin secretion to control blood sugar, increasing satiety to reduce energy intake, and promoting fat breakdown to enhance energy expenditure and basal metabolism for weight loss [1] - Currently, the drug is in the early stages of development, with high uncertainty regarding subsequent clinical trial results, significant R&D investment, and long clinical trial cycles [1]